Developing new therapies for inflammation and cancer
 
 
 
 

 
Zenyth Therapeutics became a wholly owned subsidary of CSL in November 2006.  Please click here to be redirected to the CSL website.

 
 

Documents regarding the tax implications for former Zenyth shareholders of the CSL Acquisition and Avexa Demerger:

Australian income tax implications for the former Zenyth Shareholders
Special Distribution of Avexa Shares – Market Value of Avexa Shares
CSL Acquisition Proposal Explanatory Booklet
Avexa demerger - Calculation of GCT cost base of Amrad and Avexa shares
  
 
Terms and Conditions  |  Privacy Statement © Copyright 2005-2006 Zenyth Therapeutics Limited